Search Result

Pathways Recommended:	Membrane Transporter/Ion Channel

Results for "

KATP channel inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calcium Channel (3) Potassium Channel (25) Autophagy (4) Bacterial (1) CFTR (5) Endogenous Metabolite (7) Isotope-Labeled Compounds (2) Mitochondrial Metabolism (4) P-glycoprotein (4)
By Research Areas:	Cancer (2) Cardiovascular Disease (15) Infection (1) Metabolic Disease (15) Neurological Disease (6)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Chloride Channel Calcium Channel HCN Channel CRAC Channel TRP Channel Sodium Channel Potassium Channel Piezo Channel

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162322

VU0542270	Potassium Channel	Cardiovascular Disease
VU0542270 is a selective vascular Kir6.1/SUR2B K_ATP channel inhibitor with an IC₅₀ value of 100 nM. VU0542270 has an IC₅₀ > 30 μM for the other nine members of the Kir channel family. VU0542270 can be used in the study of cardiovascular disease .

HY-128933

AMP-PNP tetralithium 1 Publications Verification Adenylyl-imidodiphosphate tetralithium	Potassium Channel	Metabolic Disease
AMP-PNP tetralithium (Adenylyl-imidodiphosphate tetralithium) is a non-hydrolysable analogue of ATP and inhibits *K_ATP* channels .

HY-14256

BMS-191095 1 Publications Verification	Potassium Channel	Cardiovascular Disease Neurological Disease
BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels .

HY-113147A

L-Palmitoylcarnitine chloride 1 Publications Verification	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits **K_ATP channel** activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147

L-Palmitoylcarnitine 1 Publications Verification	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits **K_ATP channel** activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147B

L-Palmitoylcarnitine TFA 1 Publications Verification	Endogenous Metabolite Potassium Channel	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits **K_ATP channel** activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-15206

Glibenclamide Maximum Cited Publications 21 Publications Verification Glyburide	Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glibenclamide (Glyburide) is an orally active ATP-sensitive K ⁺ channel (K_ATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of *K_ATP* and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .

HY-121183

Aprikalim RP 52891	Potassium Channel	Cardiovascular Disease
Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K+ (KATP) channels in guinea pig ventricular myocytes. Using patch-clamp techniques, it was found that aprikalim enhances KATP channel activity more effectively in Mg-NDP solution compared to standard solutions. In Mg-NDP solution, aprikalim reduced the sensitivity of KATP channels to ATP, increasing the concentration of ATP required to inhibit channel activity by half (K1) from 56 μM to 180 μM. However, this effect diminished over time. Aprikalim's ability to activate KATP channels in Mg-NDP solution suggests potential therapeutic implications in modulating cardiac excitability and may relate to changes in channel protein enzymatic activity under experimental conditions .

HY-120158

ZD0947	Potassium Channel	Neurological Disease
ZD0947 is an ATP-sensitive potassium channel activator with relatively effective activation of smooth muscle KATP channels (SUR2B/Kir6.1 and SUR2B/Kir6.2). ZD0947 partially antagonizes pancreatic KATP channels (SUR1/Kir6.2) and cardiac KATP channels (SUR2A/Kir6.2). ZD0947 is potentially used to inhibit overactive bladder (OAB) .

HY-169249

Aekatperone Z1620764636	Potassium Channel	Metabolic Disease
Aekatperone is a reversible **K_ATP channel** inhibitor, with an IC₅₀ of 9 μM. Aekatperone can be used for the research of congenital hyperinsulinism (CHI) .

HY-117255

ZM260384	Potassium Channel	Others
ZM260384 is a **K_ATP channel** opener that accelerates metabolism and inhibits the decline of guinea pig isolated diaphragm function, thereby affecting muscle contraction. ZM260384 can be used to study muscle function under hypoxic conditions .

HY-108575

Chromanol 293B	Potassium Channel CFTR	Cardiovascular Disease
Chromanol 293B is a selective blocker of the slow delayed rectifier K ⁺ current (IKs) with IC₅₀ of 1-10 μM and a weak inhibitor of **KATP channel. Chromanol 293B also blocks the CFTR chloride current with an IC₅₀** of 19 μM .

HY-113147AS

L-Palmitoylcarnitine-d3 hydrochloride	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

HY-15206S

Glyburide-d11	Isotope-Labeled Compounds Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-15206S1

Glyburide-d3 Glyburide-d₃	Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-15206R

Glibenclamide (Standard) Glyburide (Standard)	Mitochondrial Metabolism Autophagy CFTR P-glycoprotein Potassium Channel	Metabolic Disease
Glibenclamide (Standard) is the analytical standard of Glibenclamide. This product is intended for research and analytical applications. Glibenclamide (Glyburide) is an orally active ATP-sensitive K ⁺ channel (K_ATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of *K_ATP* and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .

HY-B0112

Minoxidil 5+ Cited Publications U10858	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Cancer
Minoxidil (U10858) is an ATP-sensitive potassium (K_ATP) channel opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth. Minoxidil is also a potent inhibitor of soybean lipoxygenaseare with an IC₅₀ of 20 μM .

HY-113147S1

L-Palmitoylcarnitine-d9	Isotope-Labeled Compounds Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine-d₉ is deuterium labeled L-Palmitoylcarnitine. L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits **K_ATP channel** activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-103309

ML218 2 Publications Verification	Calcium Channel	Neurological Disease
ML218 is a potent, selective and orally active *T-type Ca ²⁺ channels* (Cav3.1, Cav3.2, Cav3.3)** inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, K_ATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

HY-103309A

ML218 hydrochloride	Calcium Channel	Neurological Disease
ML218 hydrochloride is a potent, selective and orally active *T-type Ca ²⁺ channels* (Cav3.1, Cav3.2, Cav3.3)** inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 hydrochloride inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 hydrochloride has no significant inhibition of L- or N-type calcium channels, K_ATP or hERG potassium channels. ML218 hydrochloride can penetrate the blood-brain barrier .

HY-115014

Cibenzoline succinate Cifenline succinate; Ro 22-7796 succinate	Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline succinate (Cifenline succinate) is the succinate form of Cibenzoline (HY-106577). Cibenzoline succinate is an inhibitor for ATP-sensitive potassium (KATP) channel by affecting the pore-forming Kir6.2 subunit with IC₅₀ of 22.2 µM. Cibenzoline succinate affects insulin secretion and exhibits antiarrhythmic and antidiabetic activities .

HY-B0112R

Minoxidil (Standard)	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Cancer
Minoxidil (Standard) is the analytical standard of Minoxidil. This product is intended for research and analytical applications. Minoxidil (U10858) is an ATP-sensitive potassium (KATP) channel opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth. Minoxidil is also a potent inhibitor of soybean lipoxygenaseare with an IC50 of 20 μM .

HY-103309S

ML218-d9	Calcium Channel	Neurological Disease
ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].

HY-23196S

Minoxidil-d10	Potassium Channel	Neurological Disease
Minoxidil-d₁₀ (U10858-d10) is the deuterium labeled Minoxidil. Minoxidil (U10858) is an ATP-sensitive potassium (KATP) channel opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth. Minoxidil is also a potent inhibitor of soybean lipoxygenaseare with an IC50 of 20 μM[1][2][3].

HY-W037817

Dimethyl L-glutamate Dimethyl glutamate	Potassium Channel Bacterial	Infection Metabolic Disease
Dimethyl L-glutamate (Dimethyl glutamate), a membrane-permeable analog of Glutamate, can stimulate insulin release induced by Glucose. Dimethyl L-glutamate suppresses the *K_ATP* channel activities. Dimethyl L-glutamate inhibits E. gracilis growth and causes abnormal cell division. Dimethyl L-glutamate can be used in the research of diabetes, glucose transport, phosphorylation, and further metabolism .

HY-106577

Cibenzoline Cifenline; Ro 22-7796	Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a *K_ATP* channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-126704

Tedisamil KC-8857	Potassium Channel	Cardiovascular Disease
Tedisamil (KC-8857) is an antiarrhythmic compound with important biological activities. Tedisamil exhibits a significant slowing effect on heart rate, which is achieved by inhibiting the transient outward potassium current (I(to)) in the atrium. Tedisamil inhibits multiple potassium currents, including IK, K(ATP), and PKA-activated chloride channels, thereby prolonging the cardiac action potential and QT interval, and increasing cardiac reentry. Tedisamil has antiarrhythmic effects on ventricular arrhythmias and atrial flutter in animal models .

HY-106577R

Cibenzoline (Standard)	Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline (Standard) is the analytical standard of Cibenzoline. This product is intended for research and analytical applications. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a *K_ATP* channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

Cat. No.	Product Name	Target	Research Area

HY-W037817

Dimethyl L-glutamate Dimethyl glutamate	Potassium Channel Bacterial	Infection Metabolic Disease
Dimethyl L-glutamate (Dimethyl glutamate), a membrane-permeable analog of Glutamate, can stimulate insulin release induced by Glucose. Dimethyl L-glutamate suppresses the *K_ATP* channel activities. Dimethyl L-glutamate inhibits E. gracilis growth and causes abnormal cell division. Dimethyl L-glutamate can be used in the research of diabetes, glucose transport, phosphorylation, and further metabolism .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113147A

L-Palmitoylcarnitine chloride 1 Publications Verification	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Potassium Channel Endogenous Metabolite
L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits **K_ATP channel** activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147

L-Palmitoylcarnitine 1 Publications Verification	Cardiovascular Disease Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Potassium Channel Endogenous Metabolite
L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits **K_ATP channel** activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147B

L-Palmitoylcarnitine TFA 1 Publications Verification	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Potassium Channel
L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits **K_ATP channel** activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-B0112

Minoxidil Maximum Cited Publications 7 Publications Verification U10858	Cardiovascular Disease Structural Classification Alkaloids Piperidine Alkaloids Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Potassium Channel Endogenous Metabolite
Minoxidil (U10858) is an ATP-sensitive potassium (K_ATP) channel opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth. Minoxidil is also a potent inhibitor of soybean lipoxygenaseare with an IC₅₀ of 20 μM .

HY-B0112R

Minoxidil (Standard)	Structural Classification Alkaloids Piperidine Alkaloids Source classification Endogenous metabolite	Potassium Channel Endogenous Metabolite
Minoxidil (Standard) is the analytical standard of Minoxidil. This product is intended for research and analytical applications. Minoxidil (U10858) is an ATP-sensitive potassium (KATP) channel opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth. Minoxidil is also a potent inhibitor of soybean lipoxygenaseare with an IC50 of 20 μM .

Cat. No.	Product Name	Chemical Structure

HY-113147AS

L-Palmitoylcarnitine-d3 hydrochloride
L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

L-Palmitoylcarnitine-d3 hydrochloride

L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

HY-15206S1

Glyburide-d3
Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

Glyburide-d3

Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-23196S

Minoxidil-d10
Minoxidil-d₁₀ (U10858-d10) is the deuterium labeled Minoxidil. Minoxidil (U10858) is an ATP-sensitive potassium (KATP) channel opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth. Minoxidil is also a potent inhibitor of soybean lipoxygenaseare with an IC50 of 20 μM[1][2][3].

HY-15206S

Glyburide-d11
Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

Glyburide-d11

Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-113147S1

L-Palmitoylcarnitine-d9
L-Palmitoylcarnitine-d₉ is deuterium labeled L-Palmitoylcarnitine. L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits **K_ATP channel** activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-103309S

ML218-d9
ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].

ML218-d9

ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks